With its cash cache set to run out by the fourth quarter of this year, Werewolf Therapeutics is prowling the biotech landscape for a deal to keep its pipeline afloat. | With its cash cache set to run ...

Harbour BioMed is setting sail as the Solstice begins, riding the waves of biobucks potential that could reach heights up to $1.1 billion. | Harbour BioMed is setting sail as the Solstice begins, ...

The FDA has ordered MacroGenics to halt enrollment in a phase 2 trial of the biotech’s lead candidate lorigerlimab following severe side effects that led to one patient death.

Astellas Pharma and AstraZeneca are joining Bristol Myers Squibb by deploying Evinova’s AI-native platform in an effort to speed up clinical development.

Less than a year after announcing the spinout of its diabetes division, Medtronic says it is seeking $784 million in an initial public offering for the MiniMed business. | Less than a year after ...

Allurion saw its shares jump roughly 60% on Monday, Feb. 23, as the FDA signed off on the medtech’s premarket approval ...

A year after Abcuro raised $200 million to fund a phase 2/3 muscle disease trial of its anti-KLRG1 antibody, the study has ...

Labcorp expanded its partnership with PathAI to offer its FDA-cleared digital pathology platform at the life science giant’s U.S. network of anatomical pathology labs and participating hospitals.

GSK is continuing to bolster its siRNA portfolio by paying $40 million upfront for a pair of oligonucleotide therapies from China’s Frontier Biotechnologies. | GSK is continuing to bolster its siRNA ...

Novo Nordisk and its Chinese partner have reported up to 19.7% weight loss in patients who took their triple agonist for 24 weeks, illuminating a potential path forward for the Danish drugmaker as it ...

Slate Medicines has emerged with hopes of cracking the code for delivering an injectable novel drug class to prevent ...

Protara Therapeutics has touted a 66% complete response (CR) rate for its cell therapy among certain bladder cancer patients ...